1. DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial. (21st January 2022) Authors: Peyrin-Biroulet, L; Vermeire, S; D'Haens, G R; Panés, J; Dignass, A; Magro, F; Le Bars, M; Lahaye, M; Nazar, M; Ni, L; Bravatà, I; Lavie, F; Daperno, M; Lukáš, M; Armuzzi, A; Löwenberg, M; Gaya, D R; Danese, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP35 Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trial. (27th May 2021) Authors: Danese, S; Vermeire, S; D'Haens, G; Panés, J; Dignass, A; Magro, F; Nazar, M; Le Bars, M; Lahaye, M; Ni, L; Bravatà, I; Gaya, D R; Peyrin-Biroulet, L Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S032 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP40 Analysis of clinical features associated with favourable outcomes from ustekinumab treat-to-target strategy in Crohn's Disease patients in the STARDUST trial. (27th May 2021) Authors: Danese, S; Vermeire, S; Dignass, A; Panés, J; D'Haens, G; Magro, F; Le Bars, M; Nazar, M; Lahaye, M; Ni, L; Bravatà, I; Gaya, D R; Peyrin-Biroulet, L Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S039 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P091 Switching to TNFi versus non-TNFi biologics in Crohn's Disease patients: Real-world outcomes from a German claims data analysis. (27th May 2021) Authors: Antolin-Fontes, B; Borsi, A; Nissinen, R; Bravatà, I; Barthelmes, J N; Le Bars, M; Lee, J; Maywald, U; Bokemeyer, B; Wilke, T; Ghiani, M Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P301 Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: results up to Week 48 of the STARDUST trial. (27th May 2021) Authors: Danese, S; Vermeire, S; D'Haens, G; Panés, J; Dignass, A; Magro, F; Nazar, M; Le Bars, M; Lahaye, M; Ni, L; Bravatà, I; Gaya, D R; Peyrin-Biroulet, L Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S330 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗